Keyphrases
Autoantibodies
100%
Targeted Treatment
100%
AE-IPF
100%
Idiopathic Pulmonary Fibrosis
77%
Acute Exacerbation
55%
Therapeutic Plasma Exchange
55%
Historical Controls
33%
Targeted Therapy
22%
Fibrosis Progression
22%
HEp-2
22%
Intravenous Immunoglobulin (IVIg)
22%
Rituximab
22%
Matrix Metalloproteinase 7 (MMP7)
22%
Autoimmune Disease
11%
Lung Disease
11%
Sustained Response
11%
Clinical Response
11%
Critically Ill
11%
1-year Survival
11%
Serious Adverse Events
11%
Trial Registration
11%
Glucocorticoid Therapy
11%
Late Cases
11%
Pulmonary Gas Exchange
11%
Indirect Immunofluorescence
11%
Specific Treatment
11%
Severe Exacerbations
11%
Severely Ill
11%
Indirect ELISA
11%
Plasma Matrix
11%
Reduction Method
11%
Seven-level
11%
Neuroscience
Autoantibodies
100%
Pulmonary Fibrosis
100%
Blood Plasma
77%
Intravenous Immunoglobulin
22%
Glucocorticoid
22%
Matrilysin
22%
Rituximab
22%
Immunofluorescence
11%
Autoimmune Disease
11%
ELISA
11%
Lung Gas Exchange
11%
Pharmacology, Toxicology and Pharmaceutical Science
Autoantibodies
100%
Fibrosing Alveolitis
100%
Immunoglobulin
22%
Glucocorticoid
22%
Rituximab
22%
Matrilysin
22%
Adverse Event
11%
Enzyme-Linked Immunosorbent Assay
11%
Autoimmune Disease
11%
Lung Disease
11%
Immunology and Microbiology
Autoantibodies
100%
Blood Plasma
77%
Intravenous Immunoglobulin
22%
Rituximab
22%
Glucocorticoid
22%
Autoimmune Disease
11%
Immunofluorescence
11%
ELISA
11%
Lung Gas Exchange
11%
Biochemistry, Genetics and Molecular Biology
Autoantibodies
100%
Blood Plasma
77%
Intravenous Immunoglobulin
22%
Matrilysin
22%
Rituximab
22%
Glucocorticoid
22%
Immunofluorescence
11%
Lung Gas Exchange
11%